Identifies mutated JAK kinases and deregulated STAT activity as therapeutic targets in cutaneous T-cell lymphoma, suggesting new treatment avenues.
Key Points
The aim is to explore the role of mutated JAK kinases and deregulated STAT activity in cutaneous T-cell lymphoma and their potential as therapeutic targets.
Analysis of JAK kinases mutations and STAT pathway activity in cutaneous T-cell lymphoma cases.
Evaluation of therapeutic potential of targeting these mutations.
Identified specific mutations in JAK kinases associated with disease progression.
Deregulated STAT activity was prevalent in tumor samples, indicating potential for targeted therapies.